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Summary
Background: Stress (tako-tsubo) cardiomyopathy (SC) is a newly reported condition
afﬂicting older women, characterized by acute left ventricular (LV) systolic dys-
function, triggered by emotionally and physically stressful events, and occurring
without signiﬁcant coronary obstruction. Sympathetic nervous system hyperactivity
has been implicated in the pathophysiology of SC. Single nucleotide polymor-
phisms involving the adrenergic receptors (AR) might result in susceptibility to
SC.
Methods: Forty-one female SC patients were identiﬁed aged 34—89 years (mean
65) and were compared with 43 control females of similar age with respect to AR
genotype frequencies for B1 receptor (amino acid positions 389 and 49) and alpha
2c receptor (deletion 322—325).
Results: For SC patients, initial LV ejection fraction was 32± 10% vs. 62± 11% in
control patients, p < 0.05. Genotype frequencies for SC patients vs. controls were
B1 389Arg/Arg (0.49 vs. 0.51), B1 389Arg/Gly (0.49 vs. 0.49), B1 389Gly/Gly (0.02
vs. 0), B1 49 Ser/Ser (0.88 vs. 0.81), B1 49 Ser/Gly (0.12 vs. 0.16), B1 49Gly/Gly (0
vs. 0.02), alpha 2c Wt/Wt (0.93 vs. 0.86), and alpha 2c Wt/Del 322—325 (0.07 vs.
0.14); p = ns for all comparisons.
Conclusions: Genotype polymorphism frequencies for B1 receptor (amino acid posi-
tions 389 and 49) and alpha 2c receptor (deletion 322—325) are not signiﬁcantly
different in SC patients compared to female controls. These data suggest that these
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AR polymorphisms do not mediate the sympathetic nervous system hyperactivity in
SC patients.
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Introduction
Stress (tako-tsubo) cardiomyopathy (SC) is a
recently recognized acute cardiac syndrome char-
acterized by the sudden onset of regional left
ventricular (LV) systolic dysfunction typically trig-
gered by an acute emotional or physical stress. The
association of this syndrome with an acute stressful
event, particularly in older women, has suggested
to investigators a pathophysiologic role for the sym-
pathetic nervous system [1—9]. Indeed, substantial
elevations of plasma catecholamines (epinephrine,
norepinephrine, and dopamine) have been reported
in patients with stress cardiomyopathy [7].
Single nucleotide polymorphisms of the B1 and
alpha 2c adrenergic receptors result in enhanced
myocyte receptor function and enhanced synap-
tic norepinephrine release and theoretically could
result in harmful sympathetic nervous system over-
activity [10,11]. It is therefore reasonable to
consider such genetic variation within the sympa-
thetic nervous system as a predisposing factor for
this cardiomyopathy. We postulated that unique
single nucleotide polymorphisms involving the B1
adrenergic receptor (amino acid positions 389 or
49) and/or the alpha 2c adrenergic receptor (dele-
tion 322—325) might result in susceptibility to
SC.
Methods
Patient population
Between August 2001 and April 2006, 41 patients
with SC presented to the Minneapolis Heart Insti-
tute and Abbott Northwestern Hospital and also
consented to genetic analysis.
All patients were female and demonstrated the
following features: (1) acute cardiac event typi-
cally presenting with substernal chest discomfort;
(2) systolic dysfunction characterized by akine-
sia/hypokinesia of the mid and distal LV chamber
associated with a hypercontractile basal LV segment
(morphologic appearance of tako-tsubo cardiomy-
opathy); (3) absence of signiﬁcant atherosclerotic
coronary artery stenosis (i.e. ≤50% luminal nar-
rowing) in the three epicardial coronary arteries
at coronary angiography; (4) a stressful (emotional
M
o
c
l
br physical) triggering event; and (5) no morpho-
ogic evidence of myocardial infarction (absent
elayed hyperenhancement on cardiac MRI) with
ubsequent normalization of LV systolic function,
onsistent with myocardial stunning [4].
enotyping
7-cm3 blood sample was obtained from each SC
atient and frozen for subsequent genetic analysis.
enomic DNA was extracted from the sample and
drenergic receptor polymorphisms were deter-
ined as previously described [12]. Samples were
ollected on an outpatient basis after hospital
ischarge. The genotypes are referred to as wild-
ype alpha 2c-adrenoreceptor (the more common
ariant), alpha 2c Del 322—325 (the variant with
eletion of four amino acids), B1Arg389, B1Gly389,
1Ser49, and B1Gly49.
ontrol patients
or purposes of comparison, we used historical
enotype data from 43 females whose hearts had
een donated for purposes of cardiac transplan-
ation. These patients were obtained from the
atabase maintained at the University of Colorado
MRB and PN) and matched as closely as possible to
C patients with respect to age.
tatistical analyses
ontinuous variables are reported as mean± S.D.
nd assessed with paired or unpaired Student’s t-
est, as appropriate. Categorical variables were
ompared with standard chi-square test. Statistical
igniﬁcance was deﬁned as p≤ 0.05. GB-STAT statis-
ical software version 9.0 (Dynamic Microsystems,
ilver Spring, MD, USA) was used in all analyses.
he protocol and consent form for this study was
pproved 24 April 2006 by the Abbott NorthwesternN (IRB ﬁle number 2154-1E). Informed consent was
btained from each patient and the study protocol
onforms to the ethical guidelines of the 1975 Dec-
aration of Helsinki as reﬂected in a priori approval
y this institution’s human research board.
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s.olymorphisms in patients with stress (tako-tsubo)
esults
he 41 SC patients ranged in age from 34 to 89
ears (mean 65± 11 years) with a racial distribu-
ion of Caucasian (n = 40, 98%) and Hispanic (n = 1,
%). The 43 control patients ranged in age from
1 to 75 years (mean 59± 6 years, p < 0.05) with
racial distribution of Caucasian (n = 35, 82%), His-
anic (n = 3, 7%), African American (n = 1, 2%), and
nknown (n = 4, 9%). In SC patients, initial LV ejec-
ion fraction was mean 32± 10% vs. mean 62± 11%
n control patients, p < 0.05.
In SC patients, the inciting stressor was emo-
ional in 31 (76%) and physical in 10 (24%) patients.
T-segment elevation was present on initial electro-
ardiogram in 20 (49%) SC patients. Troponin T or I
as elevated at admission or during hospitalization
n 40 (98%) SC patients.
In SC patients, the wild-type alpha 2c adrenore-
eptor genotype was present in 93% of patients,
hile the heterozygous genotype (Wt/Del 322—325)
as present in 7% of patients (no SC patients were
omozygous for Del 322—325). For the B1 adrenore-
eptor (amino acid position 389), the genotype was
omozygous Arg/Arg in 49%, heterozygous Arg/Gly
n 49% and homozygous Gly/Gly in 2% of SC patients.
or the B1 adrenoreceptor (amino acid position 49),
he genotype was homozygous Ser/Ser in 88%, and
eterozygous Ser/Gly in 12% of SC patients (no SC
atients were homozygous for Gly).
The genotype frequency of polymorphisms
alpha 2c Del322—325, B1Arg389, and B1Ser49) in
C patients is compared with those of control
atients in Table 1. No signiﬁcant differences were
resent in the polymorphism frequencies between
he two groups.
iscussion
he sudden onset of SC, virtually always trig-
ered by a stressful event, intuitively suggests
pathophysiologic role for the sympathetic ner-
ous system in this condition. Indeed, plasma
atecholamines (epinephrine, norepinephrine, and
opamine) are substantially elevated in patients
uring the acute phase of this condition, often to
evels exceeding those observed in patients with
cute myocardial infarction and similar degrees
f LV dysfunction [7]. In addition, case reports
ocument the occurrence of the SC syndrome
n patients with pheochromocytoma or para-
anglioma [13,14]. Catecholamine excess could
ediate a direct cardiomyopathic effect via over-
timulation of the B1 cardiac receptor [15].
lternatively, over-stimulation of the alpha-1 and T
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alpha-2 adrenoreceptors of the small coronary
arteries and arterioles (<300m diameter) could
result in non-physiologic vasoconstriction leading
to myocardial ischemia [16]. Single nucleotide
polymorphisms within the alpha and beta adren-
ergic receptors have been proposed as a basis
for physiologic variability within the sympathetic
nervous system in humans [10,11]. Two common
polymorphisms of human B1-adrenergic recep-
tor result in either an arginine (B1Arg389) or a
glycine (B1Gly389) at amino acid position 389
[10]. Experimentally, the Arg type B1 receptor
displays increased coupling to the stimulatory G
protein resulting in increased adenylyl cyclase
activity when compared to the Gly variant [10].
Another known B1-adrenergic receptor polymor-
phism involves substitution of Gly for Ser at amino
acid position 49 (B1 49) and may also enhance B1
receptor function [17,18].
In addition, sympathetic nervous system activ-
ity is modulated by inhibitory pre-synaptic alpha
2-adrenoreceptors [19]. The alpha 2c recep-
tor controls norepinephrine release from car-
diac sympathetic nerves. In humans, a 4-amino
acid deletion polymorphism exists (alpha 2c Del
322—325) and is associated with decreased G-
protein coupling which could lead to increased
norepinephrine release and consequently sympa-
thetic over-stimulation [19].
This study demonstrates no signiﬁcant differ-
ences in the frequencies of these adrenoreceptor
polymorphisms in patients with SC when compared
to female controls. The SC patients reported in this
study are predominantly Caucasian and the poly-
morphism frequencies for other racial groups with
SC (including Asian in whom this cardiomyopathy
was ﬁrst reported) is unknown. Nonetheless, these
observations effectively exclude single nucleotide
polymorphisms of these particular adrenoreceptors
as operative in the sympathetic nervous system
over-activity observed in SC. Currently unrec-
ognized polymorphisms may emerge for future
genetic analysis. Further studies of SC should also
consider alternative hypotheses such as regional
differences in myocardial adrenergic receptor
density, asymmetry in myocardial sympathetic
innervation, or variability in those areas of the
brain which modulate cardiac sympathetic activ-
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